Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 2 clinical ...

Incyte has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently updated its clinical study ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno ...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Cantor Global Healthcare Conference on Wednesday, September 3, 2025 ...

The stock's fall snapped a seven-day winning streak.

Specifically, Incyte will look for “derisked pre-revenue or revenue-stage opportunities,” the new CEO said. Meanwhile, driving the growth of major products in the short term is necessary for ...

Incyte Corp's new chief executive, Bill Meury, outlined a growth strategy on Tuesday focused on accelerating drug development and prudent capital allocation, as the company faces the looming ...

About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and ...

Incyte also earns product royalty revenues from Novartis NVS for the commercialization of Jakafi in ex-U.S. markets. While Incyte markets Jakafi in the United States, Novartis markets the same ...